zasocitinib
takeda
['tak-279', 'psoriasis']
results from a phase 2b trial indicate that the investigational drug tak-279 significantly improved clearance of skin lesions for patients with moderate to severe plaque psoriasis. #aad2023
Pharmacy Practice News is the No. 1-rated independent monthly newspaper providing hard-hitting, timely content to 38,000 U.S.-based health-system pharmacists.